Vyome completes enrollment in POC acne trial

Vyome Biosciences Pvt. Ltd. (Delhi, India) completed enrollment of 161 patients in a proof-of-concept (POC) trial evaluating VB 1953 to treat moderate to severe acne. The double-blind, vehicle-controlled, Central American and Dominican trial is evaluating VB 1953 for the co-primary endpoints of the change in inflammatory and non-inflammatory lesions, proportion of patients with Investigator's Global Assessment (IGA) success and safety. Patients will receive once- or twice-daily topical 2% VB 1953 for up to 12 weeks. The product is a gel antibiotic with bactericidal anti-inflammatory properties...